Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Alpha subunit (1)
- Breast cancer (1)
- Carcinoma (1)
- Carcinoma, Ovarian Epithelial (1)
- Chromatin regulation (1)
-
- Drug Resistance, Neoplasm (1)
- Drug resistance (1)
- Endocrine therapy (1)
- Epigenetics (1)
- Estrogen receptor - ESR1 (1)
- Female (1)
- Humans (1)
- Hypoxia-Inducible Factor 1, alpha Subunit (1)
- Hypoxia-inducible factor 1 (1)
- MicroRNAs (1)
- NADPH Oxidases (1)
- NADPH oxidases (1)
- Neoplasm (1)
- Neovascularization (1)
- Neovascularization, Pathologic (1)
- Ovarian Neoplasms (1)
- Ovarian epithelial (1)
- Ovarian neoplasms (1)
- Pathologic (1)
- Phosphatidylinositol 3-Kinases (1)
- Phosphatidylinositol 3-kinases (1)
- Reactive Oxygen Species (1)
- Reactive oxygen species (1)
- Transcription factor (1)
- Vascular Endothelial Growth Factor A (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Ros And Mirna Dysregulation In Ovarian Cancer Development, Angiogenesis And Therapeutic Resistance, David C Stieg, Yifang Wang, Ling-Zhi Liu, Bing-Hua Jiang
Ros And Mirna Dysregulation In Ovarian Cancer Development, Angiogenesis And Therapeutic Resistance, David C Stieg, Yifang Wang, Ling-Zhi Liu, Bing-Hua Jiang
Kimmel Cancer Center Faculty Papers
The diverse repertoires of cellular mechanisms that progress certain cancer types are being uncovered by recent research and leading to more effective treatment options. Ovarian cancer (OC) is among the most difficult cancers to treat. OC has limited treatment options, especially for patients diagnosed with late-stage OC. The dysregulation of miRNAs in OC plays a significant role in tumorigenesis through the alteration of a multitude of molecular processes. The development of OC can also be due to the utilization of endogenously derived reactive oxygen species (ROS) by activating signaling pathways such as PI3K/AKT and MAPK. Both miRNAs and ROS are …
Epigenetic Mechanisms Influencing Therapeutic Response In Breast Cancer., Amaia Arruabarrena-Aristorena, Eneda Toska
Epigenetic Mechanisms Influencing Therapeutic Response In Breast Cancer., Amaia Arruabarrena-Aristorena, Eneda Toska
Kimmel Cancer Center Faculty Papers
The majority of breast cancers are estrogen receptor (ER)+ and agents targeting the ER signaling pathway have markedly increased survival for women with breast cancer for decades. However, therapeutic resistance eventually emerges, especially in the metastatic setting. In the past decade disrupted epigenetic regulatory processes have emerged as major contributors to carcinogenesis in many cancer types. Aberrations in chromatin modifiers and transcription factors have also been recognized as mediators of breast cancer development and therapeutic outcome, and new epigenetic-based therapies in combination with targeted therapies have been proposed. Here we will discuss recent progress in our understanding of the chromatin-based …